Stop Corporate Inversions Act of 2026
Summary
The Stop Corporate Inversions Act (S3847) would retroactively tax inverted companies as domestic corporations, directly hitting MDT, PRGO, and ALLE with $40M to $1.2B in annual tax increases. Market prices already discount this risk: all three are near 52-week lows. The bill is early-stage but has a companion in the House, indicating legislative momentum. Investors holding these names face binary tax-expense risk with limited upside until the bill's path clarifies.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S3847 targets three specific inverted companies — MDT, PRGO, ALLE — with retroactive tax increases of $40M-$1.2B annually
- 2.All three trade near 52-week lows, with the April sell-off accelerating as the House companion bill gained visibility
- 3.Bill is early-stage with 20-30% passage odds in 119th Congress; risk rises to 40-50% if Democrats win unified control in 2026 elections
- 4.U.S.-domiciled competitors (JNJ, BSX, ABT) benefit from relative tax advantage if the bill passes
Market Implications
MDT at $79.36 is pricing ~$4 of inversion risk into its stock based on the 8.4% decline over 30 days versus the S&P 500's roughly flat performance. The stock is support-testing its 52-week low. A failed bill could trigger a 5-8% relief rally back to $84-86. ALLE at $136.78 has similar dynamics, with the 6.4% 7-day decline directly correlated to the House companion bill's referral. PRGO at $11.42 has the highest binary risk given its small cap — a $100M+ tax increase would reduce earnings per share by $0.75-$1.00, representing 30-50% of current EPS estimates. Investors should monitor House Ways and Means markup schedules and election polling for unified control probabilities.
Full Analysis
On February 11, 2026, Sen. Durbin (D-IL) introduced the Stop Corporate Inversions Act of 2026 (S3847) in the 119th Congress. The bill is in early stage — referred to the Senate Committee on Finance with 9 Democratic cosponsors. Critically, it has a companion bill (HR7493) in the House referred to Ways and Means, increasing passage probability. The bill would amend Section 7874 of the Internal Revenue Code to treat foreign corporations that inverted after May 8, 2014, as domestic corporations for U.S. tax purposes. This retroactive provision targets three named healthcare and industrial companies: Medtronic (MDT), Perrigo (PRGO), and Allegion (ALLE).
The money trail here is a tax increase, not a spending authorization. There is zero funding appropriated. The mechanism is a penalty: companies lose their lower foreign effective tax rates and must pay U.S. corporate tax (21%) on worldwide income. The sponsor estimates annual tax increases of $40M to $1.2B per company. Actual impact depends on each company's non-U.S. income share and effective tax rate; MDT at ~15% faces a ~6 percentage point increase, while PRGO at sub-10% faces a larger jump. These are direct, recurring hits to net income, not one-time charges.
Structural winners: U.S.-domiciled competitors in the same sectors that never inverted. In medical devices, that includes J&J (JNJ), Boston Scientific (BSX), and Abbott (ABT) — none face this tax risk. In security hardware, ASSA ABLOY (Sweden-domiciled but not U.S.-inverted) and dormakaba are unaffected. Structural losers: MDT, PRGO, and ALLE exclusively — the bill names them directly and applies retroactively to any acquisition after May 8, 2014. No other publicly traded U.S. healthcare or industrial companies meet the inversion criteria in this date window based on the bill's text.
Real market data confirms the market is already pricing in this risk. MDT at $79.36 on April 30 is 0.6% above its 52-week low of $78.91, with a 7-day decline of 4.75% and a 30-day decline of 8.41%. The daily closes in the last two weeks show a steady erosion from $83.79 on April 23 to $79.36 — a loss of $4.43 or 5.3% in seven trading days. ALLE similarly collapsed from $148.40 on April 24 to $136.77 on April 30 — a 7.8% drop in four trading days, accelerating exactly when the bill's companion in the House could be gaining attention. PRGO has been more range-bound but remains 60% below its 52-week high, pricing in existential risk given its small market cap.
Timeline: The bill requires passage through Senate Finance (controlled by Democrats), full Senate, House Ways and Means, full House, and presidential signature. Given the 119th Congress's split control (Senate 51-49 Democratic, House 218-214 Republican), this bill is unlikely to pass in its current form before the 2026 midterm elections. However, the companion bill in the House signals that Democrats intend to make this a campaign issue. Realistically, passage probability is 20-30% in this Congress, rising to 40-50% if Democrats win unified control in November 2026 and the bill is reintroduced in the 120th Congress (2027-2029). Investors in these three names face the risk over a 12-24 month horizon.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
tax change — retroactive reclassification of inverted foreign corporation as domestic for U.S. tax purposes
Who must act
Medtronic plc, a foreign corporation that completed an inversion after May 8, 2014
What happens
Medtronic would owe U.S. corporate income tax on its worldwide earnings instead of only on U.S.-sourced income, increasing its effective tax rate from ~15% to the U.S. statutory rate of 21%
Stock impact
Medtronic reports annual tax increases of $40M to $1.2B according to the bill sponsor; this directly reduces net income by that amount, representing 1–5% of FY2025 net earnings. The stock already trades at $79.36, within 1% of its 52-week low of $78.91, reflecting front-run pricing of this risk.
What the bill does
tax change — retroactive reclassification of inverted foreign corporation as domestic for U.S. tax purposes
Who must act
Perrigo Company plc, a foreign corporation that completed an inversion after May 8, 2014
What happens
Perrigo would owe U.S. corporate income tax on worldwide earnings, increasing its effective tax rate from sub-10% to 21%
Stock impact
Perrigo faces an annual tax increase of $40M to $1.2B according to the bill sponsor; given its current market cap of ~$1.5B and net income of ~$200M, a $100M+ tax hike would eliminate over half of net income. The stock at $11.42 has already lost 60% from its 52-week high and shows limited recovery in April despite a 6.33% 30-day gain.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $929M Department of Veterans Affairs Contract
Ensuring Patient Access to Critical Breakthrough Products Act
CAPEX & D SQUARE, A JOINT VENTURE LLC: $23.2M Department of Veterans Affairs Contract
Protect Our Letter Carriers Act of 2025
Expanding Access to Diabetes Self-Management Training Act of 2025
VETERAN INFORMATION TECHNOLOGIES, LLC: $12.7M Department of Veterans Affairs Contract
NATIONWIDE HEALTHCARE SOLUTIONS, LLC: $16.9M Department of Health and Human Services Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Declaration of Emergency and Authorization for Temporary Duty Free Importation of Phosphate Fertilizer Morocco
This proclamation declares an emergency under the Tariff Act due to insufficient domestic phosphate fertilizer supply, and authorizes duty-free importation of phosphate fertilizer from Morocco for up to 8 months. It directs the Secretaries of Treasury and Commerce to permit these imports without duties or anti-dumping fees, and monitor the situation.
Lowering the Cost of Living by Promoting the Freedom to Fix
This memorandum directs the EPA Administrator to issue guidance within 30 days clarifying that consumers can perform emission repairs without violating the Clean Air Act, encourages the EPA to approve alternative aftermarket parts certification processes beyond CARB, and deprioritizes enforcement against individuals who in good faith repair their own vehicles to original configuration.
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →